• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Loss of HLA class I expression in prostate cancer: implications for immunotherapy.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Blades, R A
    Keating, P J
    McWilliam, L J
    George, Nicholas J
    Stern, Peter L
    Affiliation
    Department of Urology, University Hospital of South Manchester, United Kingdom.
    Issue Date
    1995-11
    
    Metadata
    Show full item record
    Abstract
    OBJECTIVES: There is currently no reliable predictor of the metastatic potential of apparently localized prostate cancer in an individual patient or satisfactory treatment for patients with advanced disease. One of the factors that may influence tumor progression is the cellular arm of the immune response, and central to this is the human leukocyte antigen (HLA) system, which acts to restrict T-cell recognition of potential tumor antigens. It has been reported in some cancers that down regulation of HLA class I expression by the tumor cells is associated with poor prognosis. In this report, HLA class I and II expression have been investigated in both benign and malignant prostate disease, first to define the extent of altered HLA expression and second to assess whether HLA expression may be related to disease progression. METHODS: HLA expression was assessed by immunohistochemistry utilizing a set of monoclonal antibodies that recognize both monomorphic determinants and the commoner HLA class I allelic products. RESULTS: In contrast to the normal HLA class I expression of the benign tissue, complete loss of HLA class I expression occurred in 34% of primary prostate cancers and 80% of lymph node metastases. When individual allelic expression was assessed, the minimum estimate of down regulation was 85% in the primary prostate cancers and 100% of the metastases. CONCLUSIONS: This investigation has demonstrated a higher rate of HLA class I loss than has been reported in other tumors and would suggest that the immune system may have an important role in the progression of prostate cancer, as well as having implications for the design and success of immunotherapy regimens in advanced disease.
    Citation
    Loss of HLA class I expression in prostate cancer: implications for immunotherapy. 1995, 46 (5):681-6 Urology
    Journal
    Urology
    URI
    http://hdl.handle.net/10541/99427
    DOI
    10.1016/S0090-4295(99)80301-X
    PubMed ID
    7495121
    Type
    Article
    Language
    en
    ISSN
    0090-4295
    ae974a485f413a2113503eed53cd6c53
    10.1016/S0090-4295(99)80301-X
    Scopus Count
    Collections
    All Christie Publications
    All Paterson Institute for Cancer Research

    entitlement

    Related articles

    • Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.
    • Authors: Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA
    • Issue date: 2000 Jul
    • Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    • Authors: Kageshita T, Ishihara T, Campoli M, Ferrone S
    • Issue date: 2005 May
    • HLA-class I expression in gastric cancer.
    • Authors: Ishigami S, Natsugoe S, Nakajo A, Arigami T, Kitazono M, Okumura H, Matsumoto M, Uchikado Y, Setoyama T, Sasaki K, Aikou T
    • Issue date: 2008 Jun 1
    • Heat shock protein expression independently predicts clinical outcome in prostate cancer.
    • Authors: Cornford PA, Dodson AR, Parsons KF, Desmond AD, Woolfenden A, Fordham M, Neoptolemos JP, Ke Y, Foster CS
    • Issue date: 2000 Dec 15
    • Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
    • Authors: Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, Gatter K, Talbot DC, Harris AL, Ganesan TS
    • Issue date: 2003 Jan
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.